Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Gold Notoginseng Technology is a biotechnology company specialized in the research, development, and industrialization of Panax notoginseng (Sanqi), a prominent medicinal herb in traditional Chinese medicine. The company utilizes advanced extraction and purification technologies to produce high-purity saponins, including Notoginsenoside R1 and Ginsenosides Rg1 and Rb1, for pharmaceutical and nutraceutical applications. Its core business focuses on cardiovascular and cerebrovascular health, leveraging a proprietary processing platform to ensure standardized, high-potency herbal solutions. Beijing Gold Notoginseng operates across the entire value chain, from standardized cultivation and deep processing to clinical research and the commercial distribution of health products. The company aims to modernize traditional herbal therapy through rigorous scientific validation and innovative biotechnology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Beijing Gold Notoginseng Technology.